Setrusumab

溃疡性结肠炎（UC）是一种病因和发病机制尚不清楚的慢性胃肠道疾病，具有频繁排便和带血腹泻的特点，严重影响患者的生活质量。近年来，治疗中重度UC的药物使用显著增加，包括生物制剂和小分子Janus激酶（JAK）抑制剂，如tofacitinib等。 2024年最新发表在《Journal of Gastroenterology and Hepatology》上的一篇真实世界研究结果，评估了联合5-ASA和托法替尼在UC患者中的意义。 研究背景与目的： 托法替尼和氨基水杨酸（5-ASA）是治疗溃疡性结肠炎（UC）的常用药物。然而，关于在接受托法替尼的患者中同时使用5-ASA的影响的证据有限。本研究探讨了5-ASA联合托法替尼在UC患者中的作用。 研究方法： 本回顾性队列研究使用来自Medical data Vision数据库的数据，包括2018年5月至2022年4月接受托法替尼治疗的UC患者。根据托法替尼剂量对患者进行分组，并评估5-ASA合用的疗效。主要终点是临床复发。 研究结果： 共有1213例UC患者纳入分析，其中5mg BID组416例，10mg BID组797例。在5mg BID组中，合并5- ASA患者的累积无复发率显著高于对照组（P < 0.0001）。多因素Cox回归分析证实，同时使用5-ASA可显著降低临床复发风险(校正危险比[HR]， 0.47；95%CI， 0.31-0.70)。 在10 mg BID组中，5-ASA组与非5-ASA组患者的累积无复发率无显著差异（P = 0.445）。同样，多因素Cox回归分析显示，同时使用5-ASA对复发风险没有显著影响(校正HR， 0.97；95% CI, 0.71-1.32)。 结论： 联合使用5-ASA降低了托法替尼5mg BID患者的复发风险，表明低剂量的益处。然而，在10 mg托法替尼BID中使用5-ASA没有观察到明显的益处。 【参考文献】 Nishida Y, Hosomi S, Fujimoto K, Kobayashi Y, Nakata R, Maruyama H, Ominami M, Nadatani Y, Fukunaga S, Otani K, Tanaka F, Fujiwara Y. Evaluating the effects of 5-aminosalicylic acid on tofacitinib treatment in ulcerative colitis. J Gastroenterol Hepatol. 2024 Nov 3. doi: 10.1111/jgh.16786. Epub ahead of print. PMID: 39489613. Document Number: ETI-CN-000882 有效截止日期：2026年11月17日 声 明 本视频/资讯/文章是由博福益普生医学团队编辑/医疗卫生专业人士撰写提供。以上内容仅限医疗卫生专业人士学术交流使用，不用于任何推广目的，且不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。 更多精彩内容  请持续关注Mayoly消化界     ✦  ✦  ✦  ✦  ✦

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:30am ET / 03:30pm GMT. A live audio webcast of the presentation can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company’s website for two weeks following the live event. About Mereo BioPharma Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has two rare disease product candidates, setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). The Company’s partner, Ultragenyx Pharmaceutical, Inc., has completed enrollment in the Phase 3 portion of a pivotal Phase 2/3 pediatric study in young adults (5 to 25 years old) for setrusumab in OI and in the Phase 3 study in pediatric patients (2 to <7 years old) in the first half of 2024. The partnership with Ultragenyx includes potential additional milestone payments of up to $245 million and royalties to Mereo on commercial sales in Ultragenyx territories. Mereo has retained EU and UK commercial rights and will pay Ultragenyx royalties on commercial sales in those territories. Setrusumab has received orphan designation for osteogenesis imperfecta from the EMA and FDA, PRIME designation from the EMA, and Breakthrough Therapy designation and pediatric disease designation from the FDA. Alvelestat has received U.S. Orphan Drug Designation for the treatment of AATD and Fast Track designation from the FDA. Following results from ASTRAEUS and ATALANTa in AATD-lung disease, the Company has aligned with the FDA and the EMA on the primary endpoints for a Phase 3 pivotal study which if successful could enable full approval in both the U.S. and Europe. In addition to the rare disease programs, Mereo has two oncology product candidates in clinical development. Etigilimab (anti-TIGIT) has completed a Phase 1b/2 basket study evaluating its safety and efficacy in combination with an anti-PD-1 in a range of tumor types and is an ongoing Phase 1b/2 investigator led study at the MD Anderson Cancer Center in clear cell ovarian cancer; Navicixizumab, for the treatment of late line ovarian cancer, has completed a Phase 1 study and has been partnered with Feng Biosciences Inc. in a global licensing agreement that includes milestone payments and royalties. Mereo has entered into an exclusive global license agreement with ReproNovo SA for the development and commercialization of leflutrozole, a non-steroidal aromatase inhibitor. Under the terms of the agreement, ReproNovo, a reproductive medicine company, is responsible for all future development and commercialization of leflutrozole. Forward-Looking Statements This press release contains “forward-looking statements” that involve substantial risks and uncertainties. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. Forward-looking statements are often identified by the words “believe,” “expect,” “anticipate,” “plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,” “estimate,” “outlook” and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company’s current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. All of the Company’s forward-looking statements involve known and unknown risks and uncertainties some of which are significant or beyond its control and assumptions that could cause actual results to differ materially from the Company’s historical experience and its present expectations or projections. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process; the Company’s reliance on third parties to conduct and provide funding for its clinical trials; the Company’s dependence on enrollment of patients in its clinical trials; and the Company’s dependence on its key executives. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law. Mereo BioPharma Contacts: Mereo +44 (0)333 023 7300Denise Scots-Knight, Chief Executive Officer Christine Fox, Chief Financial Officer Burns McClellan (Investor Relations Adviser to Mereo) +01 646 930 4406Lee Roth Investors investors@mereobiopharma.com